MitoQ
MitoQ is a triphenylphosphonium-linked ubiquinone designed to accumulate in mitochondria. Small human trials have measured selected vascular and exercise outcomes, but results remain indication-specific and should not be generalized to anti-aging or disease-treatment claims.
Pharmacokinetic model
A route-level PK model for mitoq is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- Mitochondria-Targeted Compound
- Suggested cadence
- once daily
Research behind this entry
-
Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults
Twenty older adults completed a six-week randomized, double-blind crossover trial of 20 mg/day. Flow-mediated dilation improved and plasma MitoQ was detectable, but several vascular findings came from small subgroups;…
1 published study referenced in the app, each with a plain-language summary.